CDC Vaccine Review Sparks Controversy Over Thimerosal Study Citation 
Trump’s Inflation Claims Clash With Voters’ Cost-of-Living Reality 
Is space worth the cost? Accounting experts say its value can’t be found in spreadsheets 
Senate Sets December 8 Vote on Trump’s NASA Nominee Jared Isaacman 
FDA Adds Fatal Risk Warning to J&J and Legend Biotech’s Carvykti Cancer Therapy 
Trump Signs Executive Order to Boost AI Research in Childhood Cancer 
Trump Lifts 25% Tariff on Indian Goods in Strategic U.S.–India Trade and Energy Deal 
Gold and Silver Prices Slide as Dollar Strength and Easing Tensions Weigh on Metals 
Cogent Biosciences Soars 120% on Breakthrough Phase 3 Results for Bezuclastinib in GIST Treatment 
Global Markets Slide as AI, Crypto, and Precious Metals Face Heightened Volatility 
SpaceX Starship Explodes in Texas During Test, Citing Nitrogen Tank Failure 
Blue Origin’s New Glenn Achieves Breakthrough Success With First NASA Mission 
Japan Economy Poised for Q4 2025 Growth as Investment and Consumption Hold Firm 
Dollar Near Two-Week High as Stock Rout, AI Concerns and Global Events Drive Market Volatility 
Keio University researchers have successfully transplanted into a patient with a severe spinal cord injury two million neural progenitor cells derived from other people’s iPS cells as part of a clinical study, offering hope for the paralyzed.
The patient is doing well.
Over the next year, while the patient undergoes rehabilitation, the team of doctors will see how safe and effective the treatment is.
The treatment is designed for patients with “complete paralysis” who are within two to four weeks of sustaining a spinal cord injury, called the subacute phase.
The iPS cells used were stockpiled by Kyoto University’s Center for iPS Cell Research and Application.
While rehabilitation is currently the only effective treatment for a spinal cord injury, the team believes that the transplanted cells could repair damaged neural circuits and create new tissue that can transmit signals from the brain.
The team plans to do the transplant into four more patients with spinal cord injuries.
While Japan’s Ministry of Health, Labor, and Welfare approved this clinical trial in February 2019, the process of finding suitable patients was postponed due to the COVID-19 pandemic.
